The interaction of EGFR and repair of DNA damage following chemotherapy and radiation

The epidermal growth factor receptor (EGFR) pathway is a major target for novel therapies in cancer. Monoclonal antibodies such as cetuximab, and small molecule inhibitors of EGFR including gefitinb and erlotinib, have demonstrated activity in clinical studies. However the results of combining these agents with chemotherapy and radiation have been largely disappointing. Recent research indicates interaction of the EGFR pathway with repair of DNA damage following treatment with these agents. Understanding the mechanisms by which EGFR inhibition modulates repair of DNA damage will inform design of optimal combinations for future studies and is critical to maximise benefits in the clinical setting.